Protagonist Therapeutics, Inc Stock-Based Compensation
Protagonist Therapeutics, Inc (PTGX) reported Stock-Based Compensation of $28.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- Protagonist Therapeutics, Inc share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $14.04M, a 28.64% increase year-over-year.
- Protagonist Therapeutics, Inc share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $14.52M, a 5.19% increase year-over-year.
- Protagonist Therapeutics, Inc share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $10.70M, a 17.68% increase year-over-year.
- Protagonist Therapeutics, Inc share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $10.56M, a 3.88% increase year-over-year.
- Protagonist Therapeutics, Inc share-based payment arrangement, noncash expense for fiscal 2025 was $45.97M, a 22.42% increase from fiscal 2024.
- Protagonist Therapeutics, Inc share-based payment arrangement, noncash expense for fiscal 2024 was $37.55M, a 28.20% increase from fiscal 2023.
- Protagonist Therapeutics, Inc share-based payment arrangement, noncash expense for fiscal 2023 was $29.29M, a 21.04% increase from fiscal 2022.
- Protagonist Therapeutics, Inc share-based payment arrangement, noncash expense for fiscal 2022 was $24.20M, a 47.62% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $28.56M 10-Q · filed 2026-08-05 | $39.26M derived: sum of 3 quarters · filed 2026-08-05 | $49.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $14.52M 10-Q · filed 2026-05-05 | $25.22M derived: sum of 2 quarters · filed 2026-05-05 | $35.78M derived: sum of 3 quarters · filed 2026-05-05 | $46.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $21.26M derived: sum of 2 quarters · filed 2026-02-25 | $32.17M derived: sum of 3 quarters · filed 2026-08-05 | $45.97M 10-K · filed 2026-02-25 |
| 2025-09-30 | $10.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $21.47M derived: sum of 2 quarters · filed 2026-08-05 | $35.27M 10-Q · filed 2025-11-06 | $44.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $10.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $24.71M 10-Q · filed 2026-08-05 | $33.81M derived: sum of 3 quarters · filed 2026-08-05 | $43.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $13.80M 10-Q · filed 2026-05-05 | $22.89M derived: sum of 2 quarters · filed 2026-05-05 | $33.06M derived: sum of 3 quarters · filed 2026-05-05 | $42.00M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $9.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $19.26M derived: sum of 2 quarters · filed 2026-02-25 | $28.20M derived: sum of 3 quarters · filed 2026-02-25 | $37.55M 10-K · filed 2026-02-25 |
| 2024-09-30 | $10.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.11M derived: sum of 2 quarters · filed 2025-11-06 | $28.46M 10-Q · filed 2025-11-06 | $35.06M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $8.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $18.30M 10-Q · filed 2025-08-06 | $24.90M derived: sum of 3 quarters · filed 2026-02-25 | $31.66M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $9.35M 10-Q · filed 2025-05-06 | $15.95M derived: sum of 2 quarters · filed 2026-02-25 | $22.72M derived: sum of 3 quarters · filed 2026-02-25 | $31.06M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $13.37M derived: sum of 2 quarters · filed 2026-02-25 | $21.71M derived: sum of 3 quarters · filed 2026-02-25 | $29.29M 10-K · filed 2026-02-25 |
| 2023-09-30 | $6.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $15.11M derived: sum of 2 quarters · filed 2024-11-07 | $22.69M 10-Q · filed 2024-11-07 | $28.20M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $8.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $15.93M 10-Q · filed 2024-08-06 | $21.44M derived: sum of 3 quarters · filed 2025-02-21 | $27.39M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $7.58M 10-Q · filed 2024-05-07 | $13.10M derived: sum of 2 quarters · filed 2025-02-21 | $19.05M derived: sum of 3 quarters · filed 2025-02-21 | $25.85M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $11.46M derived: sum of 2 quarters · filed 2025-02-21 | $18.27M derived: sum of 3 quarters · filed 2025-02-21 | $24.20M 10-K · filed 2025-02-21 |
| 2022-09-30 | $5.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $12.76M derived: sum of 2 quarters · filed 2023-11-02 | $18.69M 10-Q · filed 2023-11-02 | $23.71M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $6.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $12.74M 10-Q · filed 2023-08-03 | $17.76M derived: sum of 3 quarters · filed 2024-02-27 | $22.54M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $5.93M 10-Q · filed 2023-05-04 | $10.96M derived: sum of 2 quarters · filed 2024-02-27 | $15.73M derived: sum of 3 quarters · filed 2024-02-27 | $19.67M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $9.80M derived: sum of 2 quarters · filed 2024-02-27 | $13.73M derived: sum of 3 quarters · filed 2024-02-27 | $16.39M 10-K · filed 2024-02-27 |
| 2021-09-30 | $4.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $8.71M derived: sum of 2 quarters · filed 2022-11-08 | $11.37M 10-Q · filed 2022-11-08 | $13.34M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $6.60M 10-Q · filed 2022-08-04 | $8.56M derived: sum of 3 quarters · filed 2023-03-15 | $10.45M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $2.66M 10-Q · filed 2022-05-05 | $4.63M derived: sum of 2 quarters · filed 2023-03-15 | $6.51M derived: sum of 3 quarters · filed 2023-03-15 | $8.51M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $3.85M derived: sum of 2 quarters · filed 2023-03-15 | $5.85M derived: sum of 3 quarters · filed 2023-03-15 | $7.90M 10-K · filed 2023-03-15 |
| 2020-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $3.88M derived: sum of 2 quarters · filed 2021-11-03 | $5.93M 10-Q · filed 2021-11-03 | $8.09M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $4.04M 10-Q · filed 2021-08-04 | $6.20M derived: sum of 3 quarters · filed 2022-02-28 | $8.40M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $2.05M 10-Q · filed 2021-05-04 | $4.21M derived: sum of 2 quarters · filed 2022-02-28 | $6.41M derived: sum of 3 quarters · filed 2022-02-28 | $8.42M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.36M derived: sum of 2 quarters · filed 2022-02-28 | $6.37M derived: sum of 3 quarters · filed 2022-02-28 | $8.35M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $4.21M derived: sum of 2 quarters · filed 2020-11-04 | $6.19M 10-Q · filed 2020-11-04 | $8.27M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-06-30 | $2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $3.99M 10-Q · filed 2020-08-06 | $6.06M derived: sum of 3 quarters · filed 2021-03-10 | $8.08M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-03-31 | $1.98M 10-Q · filed 2020-05-07 | $4.05M derived: sum of 2 quarters · filed 2021-03-10 | $6.07M derived: sum of 3 quarters · filed 2021-03-10 | $7.71M derived: sum of 4 quarters · filed 2021-03-10 |
| 2018-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $4.09M derived: sum of 2 quarters · filed 2021-03-10 | $5.73M derived: sum of 3 quarters · filed 2021-03-10 | $6.92M 10-K · filed 2021-03-10 |
| 2018-09-30 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $3.66M derived: sum of 2 quarters · filed 2019-11-06 | $4.85M 10-Q · filed 2019-11-06 | $6.04M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $2.83M 10-Q · filed 2019-08-07 | $4.02M derived: sum of 3 quarters · filed 2020-03-10 | $5.23M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-03-31 | $1.19M 10-Q · filed 2019-05-08 | $2.37M derived: sum of 2 quarters · filed 2020-03-10 | $3.58M derived: sum of 3 quarters · filed 2020-03-10 | $4.58M derived: sum of 4 quarters · filed 2020-03-10 |
| 2017-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $2.40M derived: sum of 2 quarters · filed 2020-03-10 | $3.40M derived: sum of 3 quarters · filed 2020-03-10 | $4.24M 10-K · filed 2020-03-10 |
| 2017-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $2.21M derived: sum of 2 quarters · filed 2018-11-06 | $3.05M 10-Q · filed 2018-11-06 | $4.57M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $1.84M 10-Q · filed 2018-08-07 | $3.37M derived: sum of 3 quarters · filed 2019-03-12 | $3.81M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $843.00K 10-Q · filed 2018-05-09 | $2.36M derived: sum of 2 quarters · filed 2019-03-12 | $2.81M derived: sum of 3 quarters · filed 2019-03-12 | $2.92M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $1.97M derived: sum of 2 quarters · filed 2019-03-12 | $2.07M derived: sum of 3 quarters · filed 2019-03-12 | $2.13M 10-K · filed 2019-03-12 |
| 2016-09-30 | $448.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $554.00K derived: sum of 2 quarters · filed 2017-11-07 | $610.00K 10-Q · filed 2017-11-07 | $647.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $162.00K 10-Q · filed 2017-08-08 | $199.00K derived: sum of 3 quarters · filed 2018-03-07 | $221.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $56.00K 10-Q · filed 2017-05-10 | $93.00K derived: sum of 2 quarters · filed 2018-03-07 | $115.00K derived: sum of 3 quarters · filed 2018-03-07 | |
| 2015-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $59.00K derived: sum of 2 quarters · filed 2018-03-07 | $99.00K 10-K · filed 2018-03-07 | |
| 2015-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $62.00K 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $40.00K 10-Q · filed 2016-09-15 | |||
| 2014-12-31 | $42.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |